Predictors of Prognosis in IBD Patients

Launched by SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL · Dec 7, 2022

Keywords

ClinConnect Summary

This clinical trial, called "Predictors of Prognosis in IBD Patients," is studying how different factors might influence the health outcomes of people with inflammatory bowel diseases (IBD), such as Ulcerative Colitis and Crohn's Disease. The researchers are looking at the characteristics of patients to understand better what affects their condition and recovery. The trial is currently recruiting participants aged 65 to 74, and both men and women are welcome to join.

To participate, patients must meet certain requirements. They can either be part of a control group (healthy individuals without colitis or cancer) or be IBD patients who have never received a specific treatment called TNF-α inhibitors, or those who have been treated with it. However, individuals under 18 years old or those who have taken antibiotics or probiotics in the last three months are not eligible. If you decide to participate, you can expect to share information about your health and treatment history, which will help researchers gain valuable insights into managing IBD better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • control group: Patients who do not have colitis, cancer, and advanced polyp (the number of polyps ≥ 3, the size of polyps ≥ 1cm, high-grade adenoma, villous adenoma)
• • TNF-α inhibitor-naive IBD group: IBD patients who do not have a history of TNF-α inhibitor treatment
• • TNF-α inhibitor-treated IBD group: IBD patients who are treated with TNF-α inhibitor
• Exclusion Criteria:
• • Age under 18 years
• • Patients who were treated with antibiotics or probiotics within the last 3 months

Trial Officials